Navigation Links
Cephalon Quarterly Conference Call Invitation
Date:3/31/2008

First Quarter 2008 Earnings Conference Call Thursday, May 1, 2008, 5:00

p.m. U.S. EDT

FRAZER, Pa., March 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering first quarter 2008 results for 5:00 p.m. EDT on Thursday, May 1, 2008.

May 1, 2008 Schedule

4:10 p.m. EDT Q1 2008 results will be distributed by PRNewswire

4:50 p.m. EDT To participate in the conference call, dial 913-981-5581

and refer to Conference Code Number 7561641

5:00 p.m. EDT Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information" then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, May 14, 2008. To listen to the audio replay, dial 719-457-0820 and use the Conference Code Number 7561641.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
2. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
3. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
4. Cephalon General Counsel John E. Osborn to Resign Position
5. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
6. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
7. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. Cephalon Announces Strong Third Quarter Financial Results
11. Cephalon Quarterly Conference Call Invitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... at the Cambridge University have discovered that freshwater algae ... each other, miraculously held together only by the fluid ... today in the journal Physical Review Letters . ... consists of approximately 1,000 cells arranged on the surface ...
... Kendle (Nasdaq: KNDL ), a leading, global ... not meet analyst expectations for the first quarter of ... unprecedented biopharmaceutical industry conditions, which are resulting in longer ... fewer new requests for proposals and an increase in ...
... --BRISBANE, Calif., April 20 InterMune, Inc. (Nasdaq: ... host a live webcast of a discussion of the INFORM-1 ... at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in ... the INFORM-1 trial. Members of management from Roche, InterMune ...
Cached Biology Technology:Scientists discover 'dancing' algae 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... CAMBRIDGE, Mass. (April 2, 2009) Whitehead Institute researchers have ... have further clarified the role prions play in the inheritance ... in the field is are the prions functional are ... disease, as in "mad cow," disease in mammals," says Randal ...
... Since the days of Charles Darwin, researchers are interested ... the development of animal and plant species during their ... has already come quite a long way. But there ... animal groups that made their apparation very early in ...
... directly affect human survival and food security, especially as ... groups of social insects to cultivate crops, have harvested ... 50 million years. New results from the Smithsonian show ... combat fungi coming into the nest inside leaves, thus ...
Cached Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Early family ties: No sponge in the human family tree 2Early family ties: No sponge in the human family tree 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Goat anti-mouse gamma chain-HRP...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Biology Products: